Archive for the ‘Lymphoma / Leukemia’ Category
Monday, March 17th, 2008
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the publication of a comprehensive review article entitled, "BiTE: A new class of antibodies that recruit T cells" in the journal Drugs of the Future. BiTE(R) antibodies ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, March 6th, 2008
Solving a long-standing biological mystery, UCLA stem cell researchers have discovered that blood stem cells, the cells that later differentiate into all the cells in the blood supply, originate and are nurtured in the placenta.The discovery may allow researchers to mimic the specific embryonic microenvironment necessary for development of blood ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, February 28th, 2008
The National Institute for Health and Clinical Excellence (NICE) issued final guidance recommending the use of MabThera(R) (rituximab), as a maintenance therapy for patients with relapsed/refractory follicular non-Hodgkin lymphoma (NHL) responding to induction therapy with chemotherapy with or without rituximab. 1 This is an important breakthrough as it represents a ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, February 26th, 2008
Xenomics, Inc. (Pink Sheets:XNOM, FWB:XE7) announces that it has granted Warnex Medical Laboratories, a division of Warnex Inc., nonexclusive rights in Canada to offer NPM1 testing as a laboratory service for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML). AML is a clinically heterogeneous disease with ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, February 19th, 2008
Bayer Schering Pharma (BSP) and Genzyme Corporation, announced the availability of MabCampath® (alemtuzumab) for the first-line treatment of patients with B-CLL for whom fludarabine combination chemotherapy is not appropriate.[i] MabCampath was previously approved for the treatment of B-CLL in patients who have been previously treated with alkylating agents and have ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, February 14th, 2008
A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.Because the drug targets the immune system's B-cells, rather than the immune system's traditionally targeted T-cells -- long considered the ...
Posted in Lymphoma / Leukemia | No Comments »
Monday, January 28th, 2008
Bayer HealthCare announced, following consultation with the United States Food and Drug Administration (FDA), that it will withdraw the current liquid formulation of Leukine marketed in the US. This decision was made in light of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, January 22nd, 2008
Many of the national newspapers reported on the story of Isabella and Olivia - 4-year-old identical twin sisters who have "unlocked the secret of leukaemia". The papers go on to describe how one twin was diagnosed with leukaemia and underwent chemotherapy while the other twin did not develop the disease. ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, January 18th, 2008
A breakthrough study of identical twins has for the first time confirmed the existence of cancer stem cells that cause the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL) - backing evidence that this childhood cancer starts in the womb. The research should lead to less aggressive treatment ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, January 18th, 2008
It was once pulled off the market in the 1950s, but now a new version of the drug thalidomide is giving some cancer patients hope. When it comes to some hard-to-treat blood cancers, it's easy to see why researchers are so encouraged. When Norman Zobel ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, January 15th, 2008
Genta Incorporated (Nasdaq: GNTA) announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense(R) (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, January 3rd, 2008
Scientists at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center have received approval for a first-of-its kind study on the effect high dose vitamin C has on non-Hodgkin lymphoma patients. Researchers from the Jefferson-Myrna Brind Center of Integrative Medicine and Kimmel Cancer Center in conjunction with the National Institutes ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, January 3rd, 2008
Such body abnormalities as curvature of the spine and asymmetric lower limbs are more prevalent among children with cancer, compared to children without cancer. This suggests that a defective gene which is responsible for the abnormality may also have a role to play in cancer development, says an article in ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, December 14th, 2007
New clinical data presented at the 49th Annual Meeting of the American Society of Haematology (ASH) reveal that responses to second-generation tyrosine kinase inhibitor, nilotinib continue to improve over time in patients with resistance or intolerance to other treatments, including Glivec(R) (imatinib)*. The new data show that nilotinib produced ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, December 13th, 2007
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting ...
Posted in Lymphoma / Leukemia | No Comments »
